2,440 results match your criteria Primary CNS Lymphoma


Central Nervous System Progression in Primary Vitreoretinal Lymphoma with Bilateral and Unilateral Involvement: A Systematic Review and Meta-Analysis.

Cancers (Basel) 2022 Jun 16;14(12). Epub 2022 Jun 16.

Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.

Background: Primary vitreoretinal lymphoma (PVRL) is either unilateral or bilateral at initial presentation. Progression to a central nervous system (CNS) lymphoma is regularly observed and these patients seem to have an inferior survival. Knowledge of the predictive value of laterality for CNS progression may facilitate risk stratification and the development of more effective treatment strategies, and eventually, improve outcomes. Read More

View Article and Full-Text PDF

A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.

J Neurooncol 2022 Jun 22. Epub 2022 Jun 22.

Department of Hematology, Huashan Hospital, Shanghai, China.

Purpose: High-dose methotrexate (HD-MTX)-based chemotherapy regimen is the first-line option for primary central nervous system lymphoma (PCNSL). This prospective cohort study aimed to evaluate the efficacy and adverse effects of HD-MTX plus idarubicin (IDA) in patients with newly diagnosed immunocompetent PCNSL.

Methods: We recruited newly diagnosed PCNSL patients from January 2017 to August 2020. Read More

View Article and Full-Text PDF

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.

Sci Rep 2022 Jun 22;12(1):10551. Epub 2022 Jun 22.

Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 5 WK Roentgen Str, 02-781, Warsaw, Poland.

Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85-95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatment of 124 patients with PMBL over a period between 2004 and 2017 with the use of a protocol designed for aggressive B-cell lymphoma GMALL/B-ALL/NHL2002 including 6 cycles of alternating immunochemotherapy with intermediate-dose methotrexate in each cycle, and reduced total doxorubicin dose (100 mg/m for whole treatment). Read More

View Article and Full-Text PDF

Primary Central Nervous System Burkitt Lymphoma, Presenting with Long-Term Fluctuating Level of Consciousness: A Case Report and Literature Review on Challenges in Diagnosis and Management.

Am J Case Rep 2022 Jun 21;23:e936401. Epub 2022 Jun 21.

Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

BACKGROUND Burkitt lymphoma (BL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) rarely affecting the central nervous system (CNS) as a primary disease. Over the past years, only a few cases of primary CNS Burkitt lymphoma were reported. There is a challenge in early recognition and diagnosis of this type of brain lymphoma. Read More

View Article and Full-Text PDF

Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.

J Neurooncol 2022 Jun 20. Epub 2022 Jun 20.

Neuro-Oncology Department, Hôpital Pitié Salpêtrière, APHP, Sorbonne Université, IHU, ICM, Paris, France.

Background: Mucosae-associated lymphoid tissue (MALT) lymphomas are a rare and poorly understood form of primary central nervous system lymphoma (PCNSL). The aim of this study was to better describe these tumors, their management and their long-term prognosis.

Methods: Patients with primary CNS MALT lymphoma (PCNSML) were retrospectively selected from the database on PCNSL of the Pitié-Salpêtrière Hospital. Read More

View Article and Full-Text PDF

Syndrome of inappropriate secretion of antidiuretic hormone as an initial sign of primary central nervous system lymphomas in the hypothalamus.

Acta Neurol Belg 2022 Jun 18. Epub 2022 Jun 18.

Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Background: Primary central nervous system lymphoma (PCNSL) rarely originates in the hypothalamus. Hypothalamic PCNSL can present with various symptoms specific to dysfunction of the hypothalamus, including consciousness disturbance, cognitive impairment, hypopituitarism, and diabetes insipidus (DI). However, it remains unclear whether syndrome of inappropriate secretion of antidiuretic hormone (SIADH) can present as an initial sign of hypothalamic PCNSL. Read More

View Article and Full-Text PDF

Consolidative Autologous Stem Cell Transplantation Versus Whole Brain Radiation in PCNSL; a Nationwide Analysis.

Clin Lymphoma Myeloma Leuk 2022 May 23. Epub 2022 May 23.

Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh PA.

Background: The best consolidation strategy after induction chemotherapy in Primary CNS Lymphoma (PCNSL) remains controversial. Our objective is to estimate the overall survival (OS) for autologous stem cell transplantation (ASCT) versus whole brain radiation (WBRT) in the consolidation setting. We also sought to evaluate the factors affecting treatment selection METHODS: We identified 1620 patients with PCNSL who received chemotherapy followed by either ASCT or WBRT between 2004 and 2015 from the National Cancer Database. Read More

View Article and Full-Text PDF

Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature.

CNS Oncol 2022 Jun 13:CNS88. Epub 2022 Jun 13.

Department of Hematology, University Hospital Center, Dijon, France.

Primary CNS involvement is very rare in Hodgkin lymphoma. Here we present two cases of spinal cord dissemination. Two women of 40 and 65 years of age presented symptoms of spinal cord injury; imaging showed an intramedullary mass in T10 and T2, respectively, without vertebral involvement and upper diaphragmatic lymph nodes. Read More

View Article and Full-Text PDF

Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia.

Leuk Res Rep 2022 30;17:100331. Epub 2022 May 30.

Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan.

The optimal therapy for relapsed primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) remains unclear. We herein report a case of relapsed primary DLBCL of the CNS complicated with primary biliary cholangitis, cirrhosis, and pancytopenia that was successfully treated with bridging therapy with tirabrutinib before autologous hematopoietic stem cell transplantation (ASCT). Tirabrutinib is well tolerated and effective for relapsed primary DLBCL of the CNS with comorbidities, including cirrhosis and pancytopenia. Read More

View Article and Full-Text PDF

Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry.

Front Oncol 2022 12;12:874462. Epub 2022 May 12.

1st Department of Medicine, First Faculty of Medicine, Charles University, Prague, Czechia.

Introduction: We analyzed the incidence, risk factors of central nervous system (CNS) relapse, and outcome of CNS involvement in patients with peripheral T-cell lymphomas (PTCL) from the Czech Lymphoma Study Group Registry NiHiL (Clinical Trial gov. NCT03199066).

Materials And Methods: Out of 1,040 patients with PTCL, we identified 29 patients (2. Read More

View Article and Full-Text PDF

Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.

Front Genet 2022 12;13:878618. Epub 2022 May 12.

Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.

Identification of key genetic alterations is of importance in the targeted therapies of primary central nervous system lymphoma (PCNSL). However, only a small number of studies have been carried out in PCNSL. In this study, we further described the genetic mutations and copy number variations (CNVs) in PCNSL patients using whole-genome/exome sequencing (WGS/WES), as well as revealed their associations with patients' clinicopathological features and prognosis. Read More

View Article and Full-Text PDF

Radiophysiomics: Brain Tumors Classification by Machine Learning and Physiological MRI Data.

Cancers (Basel) 2022 May 10;14(10). Epub 2022 May 10.

Department of Scientific Computing, Florida State University, 400 Dirac Science Library, Tallahassee, FL 32306-4120, USA.

The precise initial characterization of contrast-enhancing brain tumors has significant consequences for clinical outcomes. Various novel neuroimaging methods have been developed to increase the specificity of conventional magnetic resonance imaging (cMRI) but also the increased complexity of data analysis. Artificial intelligence offers new options to manage this challenge in clinical settings. Read More

View Article and Full-Text PDF

Health care expenditures among long-term survivors of pediatric solid tumors: Results from the French Childhood Cancer Survivor Study (FCCSS) and the French network of cancer registries (FRANCIM).

PLoS One 2022 26;17(5):e0267317. Epub 2022 May 26.

Radiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.

Background: Childhood cancer survivors (CCS) may require lifelong medical care due to late effects of cancer treatments. Little is known about of their healthcare utilization and expenditures at long-term especially in publicly funded health care system. We aim to estimate and describe the health care expenditures among long-term CCS in France. Read More

View Article and Full-Text PDF

Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting.

Neurooncol Pract 2022 May 12;9(3):183-192. Epub 2022 Jan 12.

Division of Hematologic Malignancies and Stem Cell Transplantation, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Background: This study analyzes sociodemographic barriers for primary CNS lymphoma (PCNSL) treatment and outcomes at a public safety-net hospital versus a private tertiary academic institution. We hypothesized that these barriers would lead to access disparities and poorer outcomes in the safety-net population.

Methods: We reviewed records of PCNSL patients from 2007-2020 ( = 95) at a public safety-net hospital ( = 33) and a private academic center ( = 62) staffed by the same university. Read More

View Article and Full-Text PDF

Primary CNS lymphoma in the real world-Opportunities for improved outcomes in different health settings.

Neurooncol Pract 2022 May 3;9(3):159-160. Epub 2022 Apr 3.

Medical Oncology Department, Austin Health, Heidelberg, Melbourne, Victoria, Australia.

View Article and Full-Text PDF

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.

JCO Precis Oncol 2022 05;6:e2100522

Department of Medicine, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA.

Purpose: The CNS is a recurrent site of progression in anaplastic lymphoma kinase (ALK)-rearranged (ALK+) lung cancer. Lorlatinib is a third-generation ALK inhibitor developed to penetrate the CNS and overcome resistance mutations. We conducted a phase II study to evaluate the intracranial activity of lorlatinib in patients with CNS-only progression on second-generation ALK inhibitors. Read More

View Article and Full-Text PDF

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity.

Cancers (Basel) 2022 Apr 23;14(9). Epub 2022 Apr 23.

Department of Hematology and Oncology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892 Bochum, Germany.

High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is reportedly an effective treatment strategy in relapsed or refractory primary CNS lymphoma (r/r PCNSL); however, only selected patients are eligible for this treatment. We retrospectively analyzed outcome, prognostic factors, and toxicity in 59 patients with r/r PCNSL planned to receive HCT-ASCT at our institution between January 2005 and December 2021 ( = 33 < 65 years; = 26 ≥ 65 years). Median follow-up was 65 months (95% CI 21-109). Read More

View Article and Full-Text PDF

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.

Leukemia 2022 May 13. Epub 2022 May 13.

Martin-Luther Universität, Halle/Saale, Germany.

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or methotrexate-cytarabine-thiotepa-rituximab (MATRix; arm C). A second randomization allocated patients with responsive/stable disease to whole-brain irradiation (WBRT) or carmustine-thiotepa-conditioned autologous transplantation (ASCT). Read More

View Article and Full-Text PDF

A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement.

Leuk Res Rep 2022 27;17:100318. Epub 2022 Apr 27.

Department of Hematology, General Hospital of Athens 'G Gennimatas', Athens, Greece.

We report an extremely rare case of extranodal B-cell NHL: DLBCL (diffuse large B-cell non-Hodgkin lymphoma), stage IVE, presenting with heart and bilateral adrenal involvement. On admission, adrenal and thorax imaging identified large bilateral adrenal masses and a 4.6 cm mass in the right atrium wall. Read More

View Article and Full-Text PDF

The genomic and transcriptional landscape of primary central nervous system lymphoma.

Nat Commun 2022 05 10;13(1):2558. Epub 2022 May 10.

Department for Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.

Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell lymphomas (DLBCLs) confined to the central nervous system (CNS). Molecular drivers of PCNSL have not been fully elucidated. Here, we profile and compare the whole-genome and transcriptome landscape of 51 CNS lymphomas (CNSL) to 39 follicular lymphoma and 36 DLBCL cases outside the CNS. Read More

View Article and Full-Text PDF

A Rare Presentation of Primary Central Nervous System Lymphoma in an Immunocompetent Patient.

Cureus 2022 Apr 5;14(4):e23858. Epub 2022 Apr 5.

Internal Medicine, Methodist Health System, Dallas, USA.

Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin's lymphoma (NHL) that can develop in the brain, spinal cord, leptomeninges, and vitreoretinal space. The majority of cases are diffuse large B-cell lymphomas. Risk factors include immune dysfunction, prior Epstein-Barr viral infection, HIV, and a family history of non-Hodgkin's lymphoma. Read More

View Article and Full-Text PDF

An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients.

Front Oncol 2022 20;12:884724. Epub 2022 Apr 20.

Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria.

Primary central nervous system lymphomas (PCNSL) are rare CNS tumors that harbor a conspicuously longer diagnostic delay compared to other malignant brain tumors. The gold standard for diagnosis is stereotactic biopsy to acquire tissue for histopathological analysis and therefore neurosurgery plays a central role when reducing the diagnostic period is mandated. However, histopathological diagnosis could be complicated if the patient was preoperatively exposed to corticosteroids. Read More

View Article and Full-Text PDF

Primary intracranial marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the lateral ventricle: Case report and review of pathogenesis.

Surg Neurol Int 2022 29;13:181. Epub 2022 Apr 29.

Department of Neurosurgery, Staten Island University Hospital, Staten Island, New York, United States.

Background: Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal subtype of nonHodgkin's lymphoma. Ventricle-predominant PCNSL, arising in the CNS ventricular system, is a rare entity. In over 90% of cases, PCNSL is classified as diffuse large B-cell lymphoma. Read More

View Article and Full-Text PDF

Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach.

Indian J Hematol Blood Transfus 2022 Apr 18;38(2):223-234. Epub 2021 May 18.

Department of Clinical Hematology Oncology and HCT, Tata Medical Center, Newtown, Kolkata, 700160 India.

Standard treatment of primary central nervous system lymphoma (PCNSL) in countries with limited resources remains conventional chemotherapy, with or without whole brain radiotherapy (WBRT). To evaluate the treatment outcomes, prognostic factors and costs in patients with PCNSL treated with high-dose Methotrexate, vincristine and procarbazine, plus Rituximab (MVP-R) followed by consolidation with reduced dose () WBRT and Cytarabine chemotherapy. We conducted an institutional audit of the first line treatment of patients with PCNSL, who were treated with MVP-R regimen, WBRT, or both between September 2011 and January 2020. Read More

View Article and Full-Text PDF

Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.

Leuk Lymphoma 2022 May 2:1-7. Epub 2022 May 2.

Faculty of Medicine, The Hebrew University of Jerusalem, Israel.

The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown. We report our experience with rituximab, HDMTX, procarbazine and lomustine (R-MPL) given as first-line treatment in our center. Fifty-two patients between 2006 and 2019 were included. Read More

View Article and Full-Text PDF

First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18F-Fludarabine and l-[methyl-11C]Methionine.

Clin Nucl Med 2022 Apr 29. Epub 2022 Apr 29.

From the N.N. Burdenko National Medical Research Center of Neurosurgery.

Objectives: This study sought to assess 18F-fludarabine (18F-FLUDA) PET/CT's ability in differentiating primary central nervous system lymphomas (PCNSLs) from glioblastoma multiformes (GBMs).

Patients And Methods: Patients harboring either PCNSL (n = 8) before any treatment, PCNSL treated using corticosteroids (PCNSLh; n = 10), or GBM (n = 13) were investigated with conventional MRI and PET/CT, using 11C-MET and 18F-FLUDA. The main parameters measured with each tracer were SUVT and T/N ratios for the first 30 minutes of 11C-MET acquisition, as well as at 3 different times after 18F-FLUDA injection. Read More

View Article and Full-Text PDF

Advances in therapeutic strategies for primary CNS B-cell lymphomas.

Expert Rev Hematol 2022 04 25;15(4):295-304. Epub 2022 Apr 25.

Division of Onco-Hematology, European Institute of Oncology, IRCCS, Milan, Italy.

Introduction: Primary CNS lymphoma (PCNSL) has traditionally been treated with induction HD-MTX-based chemotherapy, followed by consolidation whole-brain radiotherapy. However, this approach is associated with significant neurocognitive complications, especially in older patients. Therefore, different consolidation protocols have been evaluated. Read More

View Article and Full-Text PDF

Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma.

Biomed Pharmacother 2022 Jun 20;150:112979. Epub 2022 Apr 20.

Research Network NANOTEC-Mahidol University in Theranostic Nanomedicine, Faculty of Medicine Siriraj Hospital, Mahidol University 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand; Department of Medicine (Neurology), Faculty of Medicine Siriraj Hospital, Mahidol University 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand. Electronic address:

Primary central nervous system lymphoma (PCNSL) is a form of extranodal non-Hodgkin's B-cell lymphoma limited to the CNS. The treatment of PCNSL is ineffective partly due to the blood-brain barrier (BBB) restriction of delivery of many drugs including anti-CD20 (Rituximab; RTX) which is a standard treatment for systemic B-cell lymphomas. In this study, liposome with tween-80 surface modification was fabricated and conjugated with RTX for enhancing BBB penetration to target lymphoma cells in the CNS. Read More

View Article and Full-Text PDF

Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK Positive.

Am J Clin Pathol 2022 Apr 23. Epub 2022 Apr 23.

Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Objectives: Primary central nervous system anaplastic large cell lymphoma, anaplastic lymphoma kinase positive (primary CNS ALCL, ALK+) is a rare CNS lymphoma whose description is limited to case reports. These tumors have a variable clinical course, and prognosis is primarily determined by age. We present the largest case series to date of primary CNS ALCL, ALK+, with observational data. Read More

View Article and Full-Text PDF

Primary CNS lymphoma of the corpus callosum: presentation and neurocognitive outcomes.

J Neurooncol 2022 May 21;158(1):99-109. Epub 2022 Apr 21.

Neurologie 2, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Sorbonne Université, IHU, ICM, Paris, France.

Introduction: The corpus callosum (CC) is frequently involved in primary central nervous system lymphomas (PCNSLs). In this cohort study, we described the neurocognition of patients with PCNSL-CC and its posttherapeutic evolution.

Methods: Immunocompetent patients with PCNSL-CC were identified retrospectively at the Pitié-Salpêtrière Hospital. Read More

View Article and Full-Text PDF